Martin Huber, M.D., ‘81 was recently named president and head of research at Xilio Therapeutics, a biotechnology company based in Massachusetts focusing on improving the lives of patients with cancer.
Huber, who earned a Bachelor of Science in Biology from Texas Lutheran University, has more than 30 years of experience in clinical research and oncology drug development. In this position, Huber will continue to serve as the head of research and development while leading the company in advancing tumor-selective immuno-oncology programs.
Prior to joining Xilio Therapeutics, the former TLC student served as vice-president and chief medical officer at Tesaro, Inc. and vice-president of oncology clinical research at Merck.
Huber, a medical oncologist by training, is a longtime supporter of TLU. In 2021, he established the Martin and Dorothy Huber Endowment in appreciation of the important role Texas Lutheran played in his professional career. The endowment is intended to support first generation students with opportunities similar to those provided by his parents.
In addition to his B.S. in Biology from Texas Lutheran University, Huber graduated with an M.D. degree from Baylor College of Medicine and completed his oncology training at U.T. M.D. Anderson Cancer Center in Houston, Texas.